Search research articles
Contact Us
Filters
Showing results (51-60 of 86) with videos related to
Page
of 9
Sort By:
The Journal of Clinical Investigation
|
January 17, 2018
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin, Shuang Wei, Elaine M Hurt, et al.
The Journal of Clinical Investigation
|
April 3, 2018
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin, Shuang Wei, Elaine M Hurt, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Cancer
|
January 23, 2024
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers
Alain P Algazi, James Moon, Christopher D Lao, et al.
NPJ Precision Oncology
|
January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Sandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Cancer
|
March 24, 2017
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)
Kevin Kalinsky, Sandra Lee, Krista M Rubin, et al.
The Lancet. Oncology
|
October 27, 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 15, 2020
BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases
Michelle M Kim, Hemant A Parmar, Matthew Schipper, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update
Evan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 86) with videos related to
Sort By:
Page
of 9
The Journal of Clinical Investigation
|
January 17, 2018
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin, Shuang Wei, Elaine M Hurt, et al.
The Journal of Clinical Investigation
|
April 3, 2018
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin, Shuang Wei, Elaine M Hurt, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Cancer
|
January 23, 2024
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers
Alain P Algazi, James Moon, Christopher D Lao, et al.
NPJ Precision Oncology
|
January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Sandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Cancer
|
March 24, 2017
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)
Kevin Kalinsky, Sandra Lee, Krista M Rubin, et al.
The Lancet. Oncology
|
October 27, 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 15, 2020
BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases
Michelle M Kim, Hemant A Parmar, Matthew Schipper, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update
Evan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
Page
of 9